Scaling Without Compromise: Lessons in Margin Resilience from Coloplast
Coloplast's latest slide release, picked up by TradingView, is a useful mirror for any founder obsessing over the trade-off between growth and margin discipline.
According to the release, the company posted 6% organic growth in Q3 and 9% for the first nine months of FY 2025/26, while holding EBIT margin at 26%. For business builders, these numbers tell a story about what it looks like when the operating model carries the load, not the marketing budget.
What's actually driving the number
Two segments did the heavy lifting: Chronic Care and Interventional Urology. That's the kind of growth that compounds when you understand the unit economics in your core lines and aren't constantly chasing the next category. The company reiterated its strategic priorities as innovation, efficiency, technology, and sustainability, and kept its full-year guidance for FY 2025/26 unchanged. Management also pointed to ambitious long-term growth and ROIC targets, which tells you they're not sacrificing the future to protect the current quarter.
The discipline question for your company
If you're running a business at scale, the question isn't whether you can grow 6% in a quarter. It's whether you can do it while protecting a 26% margin without raising prices or stuffing the channel. The release frames it as a deliberate mix of innovation and operational efficiency, not a single lever. In my experience, that's the accurate description. Companies that hit this combination usually did the boring work years earlier: they built the supply chain muscle, the product roadmap cadence, and the leadership team capable of holding both lines.
What to check on your own P&L
Pull up your last four quarters. Look at the segments or product lines doing the heavy lifting on organic growth. Then ask yourself whether your strategic priorities are specific enough to defend under pressure, or whether they're the kind of generic statements that sound good in a slide deck and disappear in a planning meeting. Coloplast named four, and they map cleanly to operating decisions. If yours don't, that's the bottleneck.
The hard part isn't the strategy. It's the consistency of execution quarter after quarter, especially when the easy move is to juice the top line and explain away the margin later. So here's the question worth sitting with: can you name the two operational levers you'll protect no matter what the market does next quarter?
